Veritas Genetics Announces Acquisition of Curoverse to Accelerate AI-Driven Genomic Interpretation at Scale

Recently, Yizhen Bio announced the acquisition of the bioinformatics company Curoverse. This acquisition will accelerate the application of large-scale artificial intelligence and machine learning in genomics, creating the world’s first automated interpretation platform for millions of human genomes.

The acquired party, Curoverse, was founded in 2010 and is a leading computing and bioinformatics company that provides management, computation, and sharing services for genomic and biomedical data using open-source software.

Curoverse originated from Harvard University, initially serving as the data processing provider behind the “Personal Genome Project (PGP)” launched by Harvard Medical School. The company subsequently leveraged open-source software to provide management, computational, and sharing services for genomic and biomedical data.

Prior to its acquisition, Curoverse’s core business centered on a free, open-source system built on Arvados—a free, open-source data management platform—and providing technical support services to Arvados users. Industry leaders such as the Wellcome Trust and the Sanger Institute have adopted software developed by Curoverse to manage, process, and share large-scale genomic and biomedical data, thereby facilitating applications in artificial intelligence and machine learning.

Yizhen Biotech is a biotechnology company headquartered in Boston. Founded in 2014, the company is dedicated to providing whole-genome testing and targeted screening services for hereditary cancers and reproductive health on a global scale. Yizhen Biotech’s Chinese and American teams have established affiliated companies and R&D centers in Boston, USA, and Hangzhou, China, serving as hubs for Europe, the Americas, and the Asia-Pacific region. Additionally, the company maintains three regional market headquarters in Boston, Luxembourg, and Shanghai. Yizhen Biotech was recognized by MIT as one of the “50 Smartest Companies of 2016.”

Yizhen Biotech’s founding team includes Chinese scientist Dr. Zhao Yining, Professor George Church, a pioneer in gene technology at Harvard Medical School, and American entrepreneur Mirza Cifric. Interestingly, both the buyer and the seller in this acquisition are companies affiliated with the “Church network.”

This acquisition will expand the existing collaboration between Yizhen Bio and Curoverse, further enhancing the throughput and data management capabilities of the Arvados bioinformatics platform, and enabling the effective deployment of artificial intelligence and machine learning on the platform. Data stored in Arvados is projected to exceed 10 PB this year (1 PB = 1,024 TB).

For genetic technology companies, genomic data is an invaluable resource; however, established standards for its generation and preservation have yet to be formulated.

Mirza Cifric, Co-founder and CEO of Ezon Biotech, stated, “Artificial intelligence and machine learning are leveraged to uncover these valuable insights. The industry urgently needs a standardized approach to enable rapid and secure data access, unrestricted by geography or organizational boundaries.”

Mirza Cifric, Co-founder and CEO of Yizhen Bio, explained: “Yizhen Bio is building a platform that encompasses not only sequencing technologies but, more importantly, the capacity to interpret tens of thousands, or even millions, of human whole genomes annually. The only way to achieve this goal is through large-scale deployment of artificial intelligence and machine learning.”

He believes that achieving this goal requires data generation, storage, and management to be conducted in a standardized manner. Curoverse excels in this field, enabling closer collaboration between the teams at Yizhen Biology and Curoverse.

“This is not only beneficial to Yizhen Biotech, but also advantageous for the entire genomics industry,” said Cifric.

In addition to creating Arvados, the Curoverse team is also renowned for its foundational contributions to the Common Workflow Language (CWL) standard. The CWL standard has been adopted by numerous leading research institutions for the processing and integration of genomic data. Curoverse’s data federation model enables different genomic information databases to share data with the broader community via the CWL standard, while allowing the data to remain within their original domains of creation.

Dr. Zhao Yining, Co-founder and President of Asia at Yizhen Biotech, stated, “Yizhen Biotech is collaborating with an increasing number of hospitals and research institutions in China to drive the rapid development of clinical genetic testing. By partnering with Curoverse’s experienced team, we will leverage the Arvados platform to gradually achieve large-scale automated interpretation, thereby accelerating the construction of clinical genetic testing platforms in China.”

Both parties will expand the functionality of the Arvados platform, benefiting existing customers and participants across the open-source genomics community.

Professor George Church, Co-Founder and Advisor to both companies, stated, “Globally, few companies possess over a decade of experience in integrating genomic data and applying machine learning. I am delighted to see these two teams collaborating more closely. Both Ezhou Biotech and Curoverse are advancing toward shared technological goals while remaining committed to delivering actionable, valuable insights that make such information accessible to a broader population.”

Following the acquisition, Curoverse will operate as a wholly-owned subsidiary of Yizhen Biotech. The financial terms of the transaction have not been disclosed.